Join us to learn more about Seahorse NIH Grant Applications

Stay home safe and learn from experts how to tailor your NIH grant writing for Seahorse XF technology!

Seahorse XF technology is a versatile tool which may be leveraged to support multiple specific aims within a grant. Seahorse XF technology simultaneous measurement of mitochondrial function and glycolysis enables functional assessment of cellular phenotypes. These phenotypes can be utilized by multiple scientific disciplines including: aging, cancer, cardiovascular disease, immunology, mitochondrial disease, neurodegeneration, obesity, diabetes, screening, toxicology, stem cell biology, cell physiology research, and drug discovery research.

During the session, you will learn from the experts how Seahorse XF technology empowers your NIH grant applications. Also, you will hear about NIH grant application roadmap and how to triumph your submissions. 

For questions, please contact Bahar Rizi PhD., Product Specialist, Cell Analysis Division, Agilent. 


Presented live on June 16, 2020

  Watch on demand  

Meet our speakers

Why Seahorse XF technology for your grant application

Ajit Divakaruni is an Assistant Professor of Molecular and Medical Pharmacology at the UCLA David Geffen School of Medicine. After earning his bachelor’s degree from the University of Arizona, he attended the University of Cambridge where he trained in mitochondrial bioenergetics under Martin Brand for his doctoral research. He then conducted post-doctoral research at UCSD, training under Anne Murphy and focusing on how the balance between sugar, fat, and amino acid oxidation can control cell function and fate. He continues this focus in his laboratory at UCLA, aiming to discover novel regulatory points of metabolism and develop mitochondrial proteins and metabolic pathways as therapeutic drug targets. He has conducted Seahorse XF analysis for 28 peer-reviewed manuscripts, including four methods papers.

Ajit Divakaruni, PhD
Assistant Professor, UCLA

Roadmap to a successful grant writing

Dr. Priti Mehrotra, Ph.D., is the Chief of the Immunology Review Branch (IRB), Scientific Review Program (SRP), Division of Extramural Activities, NIAID, NIH. She has almost 22 years of experience as a Health Scientist Administrator and over 20 years of research experience in immunology. As chief of IRB, over 15 years, she supervised a total of 30 Health Science Administrators (GS 13-15) and 8 Extramural Support Staff (GS 7-11) in the SRP. She is trained immunologist with broad scientific expertise relevant to global health research, including emerging and re-emerging infectious diseases including HIV/AIDS, clinical trials, asthma, and allergic diseases, cancer immunology and immunotherapy, autoimmunity, and basic and clinical immunology, including service on the NIAID IRB, regulatory experience at FDA, and experience of working across NIH, e.g. NIH US-China bilateral agreement, NCATS CTSA Program, and NIDA Opioid HEALing Communities Study. She has 22 years of experience at the NIH managing multi-billion-dollar initiatives in the scientific and technical peer review of basic, clinical, and applied research grants and contracts in Immunology, Biodefense, Bioshield, Clinical Trials, HIV/AIDS and other infectious diseases. She has a role in the interpretation, implementation, and development of extramural policies, development of initiatives, and the training, development, and supervision of SROs. She has been an invited grantsmanship presenter at National and International workshops. Dr. Mehrotra received her Ph.D. degree in Immunology. M.Sc. in Zoology, and B.S. degree with a major in Zoology, Botany, and Chemistry from Banaras Hindu University, India; Postdoctoral Visiting Scientists at the University of Tokushima, Japan. At FDA, she gained regulatory experience and joined NIAID in 1998. She is the recipient of several NIH Director and NIAID Merit Awards.

Priti Mehrotra, PhD
Immunology Review Branch Chief, NIAID, NIH

For Research Use Only. Not for use in diagnostic procedures.

©2020 Agilent Technologies